Osterweis Capital Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Osterweis Capital Management’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-174,970	Closed	-$4.96M	–	142
2020 Q4	$4.96M	Sell	174,970 -20,635	-11%	-$534K	0.3%	84
2020 Q3	$4.92M	Sell	195,605 -33,405	-15%	-$876K	0.33%	73
2020 Q2	$5.59M	Sell	229,010 -2,600	-1%	-$51.3K	0.41%	63
2020 Q1	$3.43M	Buy	231,610 +21,830	+10%	+$452K	0.28%	69
2019 Q4	$3.4M	Buy	+209,780	New	+$3.25M	0.24%	73

Other funds holding RVNC

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EWM

Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Osterweis Capital Management's RVNC Position: Q1 2021 in Review

Osterweis Capital Management sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2021, closing a stake of 174,970 shares — an estimated $4.96M sold.

Osterweis Capital Management first reported a position in RVNC in Q4 2019 and held it in 5 quarters. The position peaked at $5.59M in Q2 2020. 149 funds tracked by Wall St. Rank hold RVNC as of Q1 2021.

Osterweis Capital Management reported no remaining Revance Therapeutics, Inc. position as of Q1 2021 after selling out during the quarter.
Osterweis Capital Management sold 174,970 Revance Therapeutics, Inc. shares in Q1 2021, an estimated $4.96M.
Osterweis Capital Management first reported a position in Revance Therapeutics, Inc. in Q4 2019 and held it in 5 quarters.
Osterweis Capital Management's Revance Therapeutics, Inc. position peaked at $5.59M in Q2 2020.
149 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2021.

Based on Osterweis Capital Management's 13F filing for Q1 2021, filed 14 May 2021.